Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPS6044914B2 - malt - Google Patents
[go: Go Back, main page]

JPS6044914B2 - malt - Google Patents

malt

Info

Publication number
JPS6044914B2
JPS6044914B2 JP56033512A JP3351281A JPS6044914B2 JP S6044914 B2 JPS6044914 B2 JP S6044914B2 JP 56033512 A JP56033512 A JP 56033512A JP 3351281 A JP3351281 A JP 3351281A JP S6044914 B2 JPS6044914 B2 JP S6044914B2
Authority
JP
Japan
Prior art keywords
koji
monascus
days
rice
malt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP56033512A
Other languages
Japanese (ja)
Other versions
JPS57146570A (en
Inventor
章 遠藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP56033512A priority Critical patent/JPS6044914B2/en
Publication of JPS57146570A publication Critical patent/JPS57146570A/en
Publication of JPS6044914B2 publication Critical patent/JPS6044914B2/en
Expired legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

【発明の詳細な説明】 本発明はコレステロール低下作用と血糖低下作用の2つ
の薬理作用を兼備する新規な麹に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel koji that has two pharmacological actions: cholesterol-lowering action and blood sugar-lowering action.

麹は穀類又はその副産物を中心とする澱粉質物にかひ類
を繁殖させたものであり、日本、中国、台湾、香港をは
じめとする東南アジア諸国で古くから食品の加工・製造
に広く利用されている。
Koji is a type of malt grown on starchy substances such as grains or their by-products, and has been widely used for food processing and manufacturing in Southeast Asian countries including Japan, China, Taiwan, and Hong Kong since ancient times. There is.

日本酒、焼酎、泡盛、味淋、甘酒、食酢、しよう油、み
そ、漬物(獣肉、魚肉、山菜、野菜、豆腐等)をはじめ
中国、台湾の黄酒(紹興酒、紅酒等)、白酒(こうりや
ん酒等)、豆腐乳、獣肉の漬物、ソーセージ(香腸)等
は麹を利用した加工食品の代表的なものである。また、
伝統的な固体麹に加えて、近年液体麹も確立され、食品
の加工・製造の外にアルコール発酵、特定の天然色素や
酵素の製造にも利用されるようになつた。麹は原料とな
る澱粉質物の種類により米麹、麦麹、皺麹、糠麹等に分
類されると共に、繁殖するかびの種類により黄麹菌を使
用する黄麹、黒麹菌を使用する黒麹、及び紅麹菌を使用
する紅麹等にも分類される。
Sake, shochu, awamori, miso, amazake, vinegar, soybean oil, miso, pickles (meat, fish, wild plants, vegetables, tofu, etc.), as well as Chinese and Taiwanese yellow wine (Shaoxing wine, red wine, etc.), baijiu (koriyan sake) etc.), tofu milk, pickled animal meat, sausage (intestine), etc. are typical processed foods that use koji. Also,
In addition to traditional solid koji, liquid koji has recently been established and is now used in food processing and manufacturing, as well as alcohol fermentation and the production of certain natural pigments and enzymes. Koji is classified into rice koji, barley koji, wrinkled koji, bran koji, etc. depending on the type of starchy material used as the raw material, and depending on the type of mold that grows, there are 4 types: yellow koji using yellow koji mold, black koji using black koji mold, It is also classified as red yeast rice, etc., which uses red yeast mold.

それぞれの麹にはアミラーゼ、プロテアーゼ等の酵素類
による澱粉質、高分子物質に対する氷解作用、並びに食
品に特有の香味と色調を賦与する機能がある。一方、近
年、わが国においても、食品の西欧化並びに高級化に伴
い、高脂血症(特に高コレステロール血症)及び血糖上
昇に起因する糖尿病、肥満等の代謝性疾患が急増してい
る。
Each type of koji has the function of melting starch and polymeric substances through enzymes such as amylase and protease, as well as imparting a unique flavor and color tone to foods. On the other hand, in recent years, metabolic diseases such as diabetes and obesity caused by hyperlipidemia (particularly hypercholesterolemia) and elevated blood sugar have been rapidly increasing in Japan due to the Westernization and high-quality food products.

しかしなが・ら、これらの疾患に対する満足な予防・治
療法は未だ確立されていない。そこで、本発明者はこれ
ら疾患の予防を食生活の面から進めることを目的として
、食品加工・製造に幅広く使用されている各種麹に着目
し、鋭意研究を行つた。
However, satisfactory prevention and treatment methods for these diseases have not yet been established. Therefore, the present inventor focused on various types of koji that are widely used in food processing and manufacturing, and conducted intensive research with the aim of promoting the prevention of these diseases from the aspect of dietary habits.

その結果、多くの麹菌の中で、モナスカス属に属する特
定のかびを培養して得られる麹が、麹本来の上記機能を
外に優れたコレステロール低下作用及び血糖低下作用を
兼備していることを見出し、本発明を完成した。すなわ
ち、本発明は、コレステロール低下作用と血糖低下作用
を有する麹を提供するものである。
As a result, we found that among many types of koji mold, koji obtained by culturing a specific mold belonging to the genus Monascus has excellent cholesterol-lowering and blood sugar-lowering effects in addition to the above-mentioned functions inherent in koji. The present invention has been completed. That is, the present invention provides koji having a cholesterol-lowering effect and a blood sugar-lowering effect.

本発明における上記条件を具備したモナスカス属に属す
るかびとしては、例えば、モナスカス・パキシー(IF
O8201)、モナスカス・ピロウサス(IFO448
0、IFO4520)、モナスカス・プビゲルス(IF
O4521)、モナスカス、ルーベル(No、1005
、IFO9203、 ATCC13692、 ATCC
15670、ATCCl624O、、ATCCl636
6、ATCCl6384)、モナスカス・ビトレウス(
IFO7537、IFO4532)、モナスカス◆パー
プレウス(AI{U945l、ATCCl638\AT
CCl638阪ATCCl6436)、モナスカス◆ル
プロパンクタタス(ATCCl6368)およびモナス
カス属ATCCl637Oll6433、16434、
1666氏16772、16773s1677屯167
75等が挙げられる。
Examples of molds belonging to the genus Monascus that meet the above conditions in the present invention include Monascus paxii (IF
O8201), Monascus pilousus (IFO448)
0, IFO 4520), Monascus pubigerus (IF
O4521), Monascus, Rubel (No. 1005)
, IFO9203, ATCC13692, ATCC
15670, ATCCl624O,, ATCCl636
6, ATCCl6384), Monascus vitreus (
IFO7537, IFO4532), Monascus ◆ Purpureus (AI{U945l, ATCCl638\AT
CCl638Oll6436), Monascus ◆ Lupropanctatus (ATCCl6368) and Monascus ATCCl637Oll6433, 16434,
1666 Mr. 16772, 16773 s 1677 ton 167
75 etc. are mentioned.

またこれらの変調または変異株も利用できる。これら菌
株はすべて公知のもので、モナスカス・ルーベルNO.
lOO5は通産省工業技術院微性物工業技術研究所に昭
和5拝2月16印こ保管委託を申請し、その受託番号は
微工研菌寄第4822号(FERM−PNO.4822
)である。その他の菌株はすべて財団法人発酵研究所(
大阪市淀川区十三本町2−17−85)に寄託されてお
り、容易に入手しうるものてある。上記の各菌株の中で
もモナスカス・ピロウサスIFOO452Olモナスカ
ス●プビゲルスIFO452l及びモナスカス・ビトレ
ウスIFOO7537が本発明に最も適している。
Modified or mutant strains of these can also be used. All of these strains are known, including Monascus rubel NO.
lOO5 applied to the Ministry of International Trade and Industry's Agency of Industrial Science and Technology, Institute of Fine Chemicals Industrial Technology, to entrust the storage of the seal on February 16, 1932, and the accession number is FERM-PNO.4822.
). All other strains are from Fermentation Research Institute (
It has been deposited at 2-17-85 Jusanhonmachi, Yodogawa-ku, Osaka City, and is easily available. Among the above-mentioned strains, Monascus pilousus IFOO452O1, Monascus pubigerus IFO4521, and Monascus vitreus IFOO7537 are most suitable for the present invention.

本発明の麹はモナスカス属に属する上記かびを常法によ
つて培養することにより製造される。
The koji of the present invention is produced by culturing the above-mentioned mold belonging to the genus Monascus by a conventional method.

本発明の麹の製造原料としては、当該かびの培養に公知
の栄養源はすべて利用できる。例えば、米類、麦類、大
豆、小豆、腕豆等の豆類、トウモーロコシ、コウリヤン
、粟、ソバ等の穀類及び雑穀類をはじめそれらの副産物
である糠、皺、胚芽、籾穀等があげられる。これらの原
料は単独もしくは必要に応じて2種以上混合して利用す
ることができる。また、必要とするときはこれらの原料
に.他の炭素源、窒素源、無機塩、金属塩等を加えるこ
ともてきる。本発明のモナスカス属のかびは5〜40′
Cで生育するが、コレステロール低下作用と血糖低下作
用の2つの薬理作用を兼備した麹を製造するには、20
〜40′Cて好気的に培養するのが好ましい。
As raw materials for producing the koji of the present invention, all known nutritional sources for culturing the mold can be used. Examples include rice, wheat, legumes such as soybeans, adzuki beans, and brachia, grains and millet such as corn, kouryan, millet, and buckwheat, as well as their by-products such as bran, wrinkles, germ, and paddy. . These raw materials can be used alone or in combination of two or more kinds as required. Also, when necessary, use these raw materials. Other carbon sources, nitrogen sources, inorganic salts, metal salts, etc. can also be added. The mold of the genus Monascus of the present invention is 5 to 40'
In order to produce koji that grows at
It is preferable to culture aerobically at ~40'C.

好気的培養法としては、通常用いられている方法、例え
ば固体培養法による固体麹の製造法及び通気攪拌培養法
、振とう培養法による液体麹の製造法が採用される。培
養あるいは培地滅菌中消泡を必要くとするときはシリコ
ンオイル、界面活性剤等の消泡剤を使用できる。培養は
コレステロール低下作用と血糖低下作用の2つの薬理作
用が十分検出できるようになる迄続けるが、通常は3−
14日間が好ましい。
As the aerobic culture method, commonly used methods are employed, such as a method for producing solid koji using a solid culture method, a method for producing liquid koji using an aerated stirring culture method, and a method for producing liquid koji using a shaking culture method. When antifoaming is required during culture or medium sterilization, antifoaming agents such as silicone oil and surfactants can be used. Culture is continued until the two pharmacological effects of cholesterol-lowering and blood sugar-lowering can be sufficiently detected, but usually 3-
14 days is preferred.

また、固体培養法(固体麹法)の場合は培養途中で麹の
水分含量調節を目的として常法により散水を行うことも
できる。斯くして得られる本発明の麹は、麹の利用法と
して公知のすべての用途に利用できる。
In addition, in the case of a solid culture method (solid koji method), watering can be performed by a conventional method during the cultivation for the purpose of adjusting the water content of the koji. The koji of the present invention thus obtained can be used for all known uses of koji.

例えば、我が国の伝統食品である清酒、焼酎、泡盛、味
淋、甘酒、白酒、食酢、しよう油、みその製造;なす、
大根、白菜、かぶ等の野菜類の漬物の製l造;いか、か
つお等の魚貝類の塩類及び漬物類の製造;とり、ぶた肉
等の肉類の漬物類の製造;豆腐の漬物(にゆうふ、とう
ふよう等)の製造;中国、台湾、香港等他のアジア諸国
の伝統食品である白酒(こうりやん酒等)、黄酒(紹興
酒、紅露酒等)、豆腐乳、獣肉の漬物類、ソーセージ等
の製造;及び発酵法によるアルコールの製造等に使用し
て、その生産物にコレステロール低下作用及び血糖低下
作用を具有せしめることができる。また、必要に応じて
、、麹をあらかじめ水または溶媒類で処理して得られる
抽出物または処理麹の状態で上述の用途に供することも
できる。当該麹の毒性は経口投与で、何れもLD5Oが
1g/Kg以上と極めて低く、麹そのものは上記抽出物
を単独または適当な賦形剤、増量剤、食品類と共に粉剤
、カプセル剤、錠剤、液剤の形で健康食品、自然食品と
しても利用できる。
For example, the production of our country's traditional foods such as sake, shochu, awamori, ajirin, amazake, baijiu, vinegar, soy oil, and miso; eggplant;
Manufacture of pickled vegetables such as radish, Chinese cabbage, and turnip; Manufacture of salts and pickles for fish and shellfish such as squid and bonito; Manufacture of pickled meat such as chicken and pork; Tofu pickles Manufacture of traditional foods from China, Taiwan, Hong Kong, and other Asian countries such as baijiu (kouriyanjiu, etc.), yellow wine (shaoxingu, hongrojiu, etc.), tofu milk, pickled meat, and sausages. and in the production of alcohol by fermentation, etc., to impart cholesterol-lowering and blood sugar-lowering effects to the products. Furthermore, if necessary, the koji can be treated in advance with water or a solvent and then used in the form of an extract or treated koji for the above-mentioned purposes. The toxicity of the koji is extremely low when administered orally, with an LD5O of 1 g/Kg or more. It can also be used as a health food or natural food.

また、当該麹または抽出物に安定化剤を加えたり、ある
いは他の薬理作用をもつた食品及ひ医薬品と併用するこ
ともできる。当該麹または抽出物を健康食品等として用
いる場合、その投与量は健康状態によつて異なるが、通
常乾燥麹の重量に換算して1〜50g/日、特に1〜1
0gの径口投与が好ましい。以下に本発明の実施例をあ
けて説明する。実施例 1 (1)モナスカス・パキシ一1F08201を蒸煮滅菌
した梗米(白米)に接種し、常法により30℃で10日
間培養して1米麹ョを得た。
Furthermore, a stabilizer may be added to the koji or extract, or it may be used in combination with foods and medicines that have other pharmacological effects. When using the koji or extract as a health food, etc., the dosage varies depending on the health condition, but is usually 1 to 50 g/day, especially 1 to 1
A bolus dose of 0 g is preferred. Examples of the present invention will be explained below. Example 1 (1) Monascus paxi-1F08201 was inoculated into steam-sterilized steamed rice (white rice) and cultured at 30° C. for 10 days by a conventional method to obtain 1 rice malt.

この米麹の一部を粉砕し、水にけんだくして充分攪拌し
、水に対して充分透析した。
A portion of this rice malt was ground, suspended in water, thoroughly stirred, and thoroughly dialyzed against water.

透析内液を凍結乾燥にかけて乾固し、更に粉砕して微粉
として1水処理米麹ョを得た。(il)体重約3k9の
ウサギに上で得られた米麹を1日当り3gすつ5日間餌
と混合して投与し、投与開始前、5日間投与後にそれぞ
れ耳静脈より採血し、常法により血清コレステロール値
を測定した。
The dialyzed solution was freeze-dried to dryness and further ground to obtain a fine powder of water-treated rice malt. (il) The rice malt obtained above was administered to a rabbit weighing approximately 3k9 by mixing it with food for 5 days at a rate of 3 g per day. Blood was collected from the ear vein before the start of administration and after 5 days of administration, and blood was collected by the usual method. Serum cholesterol levels were measured.

その結果、投与開始前にくらべて米麹を投与した場合に
は血清コレステロール値が24%低下した。(Ill)
体重160−180gのウイスタ一系雄性ラツトをT2
4時間絶食させ、デン粉(煮沸溶解したもの)1g/K
9を経口投与した。
As a result, serum cholesterol levels decreased by 24% when rice malt was administered compared to before the start of administration. (Ill)
T2 male Wista rats weighing 160-180 g
Fasted for 4 hours, starch (boiled and dissolved) 1g/K
9 was orally administered.

これと同時に上で得られた水処理米麹500m9/Kg
を経口投与し、30分後及び1時間後にそれぞれ尾静脈
により採血し、常法により血糖値(血中グルコース量)
を1測定した。その結果、デン粉のみを与えた対照群に
くらべ垂水処理米麹の投与を受けた群では血糖値が3扮
後で23%、1時間後では21%それぞれ低下していた
。実施例 21 (1)モナスカス●ピロウサスIFO448Oを蒸煮滅
菌した脱脂糠(70%の水を混合)に接種し、常法によ
り25゜Cで14日間培養して1糠麹ョを得た。
At the same time, 500m9/Kg of water-treated rice malt obtained above
was administered orally, blood was collected from the tail vein 30 minutes and 1 hour later, and the blood sugar level (blood glucose level) was determined using a conventional method.
One measurement was taken. As a result, blood sugar levels in the group receiving Tarumi-treated rice malt decreased by 23% after 3 servings and by 21% after 1 hour, compared to the control group given only starch. Example 21 (1) Monascus Pilousus IFO448O was inoculated into defatted rice bran (mixed with 70% water) that had been sterilized by steaming, and cultured at 25°C for 14 days in a conventional manner to obtain 1 bran malt.

この糠麹の一部を実施例1と同じ方法により水処理、透
析、乾固及び粉砕にかけ1水処理糠2麹ョを得た。(1
1)実施例1と同じ方法により糠麹(3gずつ5日間投
与)のコレステロール低下作用を調べた結果、投与前に
くらべ18%の低下がみられた。
A portion of this bran koji was subjected to water treatment, dialysis, drying and pulverization in the same manner as in Example 1 to obtain 1 water-treated bran and 2 koji. (1
1) The cholesterol-lowering effect of rice bran bran (administered at 3 g doses for 5 days) was investigated using the same method as in Example 1. As a result, a decrease of 18% was observed compared to before administration.

また、実施例1と同じ方法により血糖低下作冫用を調べ
たところ(水処理糠麹150m9/K9投与)3扮後及
び1時間後の血糖値は対照群にくらべ投与群てはそれぞ
れ33%及び19%の低下がみられた。実施例 3 (1)水を加え蒸煮滅菌したパン粉にモナスカス・プビ
ゲルスIFO452lを接種し、常法により35で10
日間培養してパン粉麹を得た。
In addition, when the effect of lowering blood sugar was investigated using the same method as in Example 1 (water-treated rice bran koji 150m9/K9 administration), the blood sugar levels after treatment and after 1 hour were 33% each in the administration group compared to the control group. and a decrease of 19% was observed. Example 3 (1) 452 liters of Monascus pubigerus IFO was inoculated into breadcrumbs that had been sterilized by steaming with water added, and 35 to 10
Bread crumb koji was obtained by culturing for days.

(11)実施例1と同じ方法によりパン粉麹(2gずつ
5日間投与)のコレステロール低下作用を調べた結果、
投与前にくらべ19%の低下がみられた。
(11) As a result of investigating the cholesterol-lowering effect of bread crumb koji (2 g administered for 5 days) using the same method as in Example 1,
A 19% decrease was observed compared to before administration.

また、実施例1と同じ方法によりパン粉麹の血糖低下作
用を調べたところ(100m9/K9投与)3紛後及び
1時間後の血糖値は対照群にくらべ投与群では27%及
び29%の低下がみられた。
In addition, when the blood sugar lowering effect of bread crumb koji was investigated using the same method as in Example 1 (100m9/K9 administration), the blood sugar levels after 3 minutes and 1 hour were lower in the administered group by 27% and 29% compared to the control group. was seen.

実施例 4 (1)W!.に少量の籾穀と60%の水を加え、滅菌し
たものにモナスカス・ルーベルNO.lOO5を接種し
、常法により25℃で12日間培養して皺麹を得た。
Example 4 (1) W! .. Add a small amount of rice grain and 60% water to the sterilized mixture and add Monascus Rubel NO. 1005 was inoculated and cultured at 25° C. for 12 days by a conventional method to obtain wrinkled koji.

この皺麹に5倍量の70%アセトンを加えて室温で処理
して抽出液を得た。
Five times the amount of 70% acetone was added to this wrinkled koji and treated at room temperature to obtain an extract.

抽出液を減圧下で乾固して皺麹抽出物を得た。1)実施
例1と同じ方法により鈑麹抽出物のコレステロール低下
作用を調べた結果(100m9ずつ5日間投与)、投与
前にくらべ血中コレステロール値が36%低下した。
The extract was dried under reduced pressure to obtain a wrinkled koji extract. 1) As a result of examining the cholesterol-lowering effect of the sheet koji extract using the same method as in Example 1 (administering 100 m9 for 5 days), the blood cholesterol level was reduced by 36% compared to before administration.

また、実施例1と同じ方法により皺麹抽出物の血糖低下
作用をみたところ(但し、デン粉の代わりに2g/Kg
の蔗糖を経口投与)、皺麹抽出物200m9/K9経口
投与した投与群では3紛後及び1時間後で対照群にくら
べそれぞれ21%及び44%の血糖低下がみられた。
In addition, the blood sugar-lowering effect of Ajikoji extract was examined using the same method as in Example 1 (however, 2 g/Kg was used instead of starch).
In the group to which 200 m9/K9 of Koji Koji extract was orally administered, a 21% and 44% decrease in blood sugar was observed after 3 doses and 1 hour later, respectively, compared to the control group.

起施例 5 1)脱脂糖4%、パン粉2%を含む液体培地を滅菌し、
それにモナスカス・ビトレウスIFO7537を接種し
、常法により25%で10日間好気的に培養した。
Example 5 1) Sterilize a liquid medium containing 4% defatted sugar and 2% bread crumbs,
It was inoculated with Monascus vitreus IFO7537 and cultured aerobically for 10 days at 25% by a conventional method.

この培養液(液体麹)を凍結乾燥法により乾固して1乾
燥麹ョを得た。11)実施例1と同じ方法により乾燥麹
の血中コレステロール低下作用を調べたところ(2gず
つ5日間投与)、投与前にくらべ投与後の血中コレステ
ロール値は27%低下した。
This culture solution (liquid koji) was dried by freeze-drying to obtain one dried koji. 11) When the blood cholesterol lowering effect of dried koji was investigated using the same method as in Example 1 (administered 2 g for 5 days), the blood cholesterol level after administration was reduced by 27% compared to before administration.

また実施例4と同じ方法により血糖値を調べたところ(
乾燥麹100m9/K9投与)、対照群にくらべ投与群
では3紛後で19%、1時間後て31%それぞれ血糖値
の低下がみられた。
In addition, blood sugar levels were examined using the same method as in Example 4 (
(dry koji 100m9/K9 administration), compared to the control group, blood sugar levels in the treated group decreased by 19% after 3 doses and by 31% after 1 hour, respectively.

実施例 6 (1)モナスカス・ピロウサスIFO452Oを蒸煮滅
菌した白米に接種し、常法により好気的に35℃で7日
間培養後乾燥して1米麹.を調製した。
Example 6 (1) Monascus pilousus IFO452O was inoculated into steam-sterilized white rice, cultured aerobically at 35°C for 7 days using a conventional method, and then dried to produce one rice malt. was prepared.

(11)体重約3k9の白色ウサギ(オス)に上て得た
米麹を1日当り3gすつ5日間径口投与し、常法により
採血して血清コレステロール値を測定した。その結果、
米麹投与前にくらべ投与5日後の血清コレステロール値
は19%低下した。(Ill)体重160−180gの
ウイスタ一系雄性ラツトを24時間絶食させ、デン粉(
煮沸溶解したもの)1g/Kgを経口投与した。これと
同時に上て得られた米麹(粉砕したもの)500mg/
K9経口投与し、3紛後及び1時間後にそれぞれ尾静脈
より採血し、常法により血糖値を測定した。その結果、
デン粉のみ与えた対照群(6匹)にくらべ米麹投与群(
6匹)では血糖値が3扮後で17%、1時間後で20%
それぞれ低下した。実施例 7 (1)モナスカス◆ルーベルIFO92O3を実施例6
と同じ方法により35℃で10日間培養して1米麹ョを
得た。
(11) The rice malt obtained from the rat was orally administered to white rabbits (male) weighing approximately 3k9 for 5 days at a rate of 3 g per day, and blood was collected in a conventional manner to measure serum cholesterol levels. the result,
Five days after administration, serum cholesterol levels decreased by 19% compared to before administration of rice malt. (Ill) Male Wista rats weighing 160-180 g were fasted for 24 hours and starch (
(boiled and dissolved) 1 g/Kg was orally administered. At the same time, 500mg of rice malt (pulverized) obtained
K9 was orally administered, and blood was collected from the tail vein 3 and 1 hour later, and blood sugar levels were measured using a conventional method. the result,
Compared to the control group (6 animals) given only starch flour, the rice malt administered group (6 animals)
In 6 animals), the blood sugar level was 17% after 3 treatments and 20% after 1 hour.
Each decreased. Example 7 (1) Monascus ◆ Rubel IFO92O3 Example 6
One rice malt was obtained by culturing at 35°C for 10 days in the same manner as above.

(11)実施例6と同じ方法により上記米麹のコレステ
ロールの低下作用をしらべた結果(3gずつ5日間投与
)、投与直前にくらべ16%の低下がみられた。
(11) As a result of examining the cholesterol-lowering effect of the above rice malt using the same method as in Example 6 (administering 3 g for 5 days), a 16% reduction was observed compared to immediately before administration.

実施例 8 (1)モナスカス・ビトレウスIFO4532を実施例
6と同じ方法により25゜Cで12日間培養し1米麹ョ
を得た。
Example 8 (1) Monascus vitreus IFO4532 was cultured at 25°C for 12 days in the same manner as in Example 6 to obtain 1 rice malt.

(11)実施例6と同じ方法により上記米麹のコレステ
ロール低下作用を調べた結果(3gずつ5日間投与)、
投与直前にくらべ23%の低下がみられた。
(11) As a result of examining the cholesterol-lowering effect of the above rice malt using the same method as in Example 6 (administering 3 g for 5 days),
A 23% decrease was seen compared to just before administration.

(111)実施例6と同じ方法により上記米麹の血糖低
下作用を調べた結果(500m9/Kg経口投与)、デ
ン粉のみを投与した対照群(6匹)にくらべ、米麹投与
群(6匹)では3吟後及び1時間後でそれぞれ22%及
び19%の血糖値の低下がみられた。
(111) As a result of examining the hypoglycemic effect of the above rice koji using the same method as in Example 6 (500 m9/Kg oral administration), the rice malt administration group (6 animals) compared to the control group (6 animals) receiving only starch. A decrease in blood sugar level of 22% and 19% was observed after 3 and 1 hour, respectively.

実施例 9 (1)モナスカス◆パープレウスAHU945lを実施
例6と同じ方法により30℃で7日間培養して0米麹ョ
を得た。
Example 9 (1) Monascus ◆purpureus AHU945l was cultured at 30°C for 7 days in the same manner as in Example 6 to obtain 0 rice malt.

(Ii)実施例6と同じ方法により上記米麹のコレステ
ロール低下作用を調べた結果(3gずつ5日間投与)、
投与直前にくらべ29%の低下がみられた。
(Ii) As a result of examining the cholesterol-lowering effect of the above rice malt using the same method as in Example 6 (administering 3 g for 5 days),
A 29% decrease was observed compared to immediately before administration.

実施例 10 2モナスカス・パープレウスATCCl6386を蒸煮
滅菌した脱脂糠(70%の水を混合)に接種し、常法に
より好気的条件下で30℃で10日間培養して1糠麹ョ
を得た。
Example 10 2 Monascus purpureus ATCCl6386 was inoculated into defatted rice bran (mixed with 70% water) that had been sterilized by steaming, and cultured in a conventional manner at 30°C under aerobic conditions for 10 days to obtain 1 bran malt. .

(Ii)実施例6と同じ方法により上記糠麹のコレス・
テロール低下作用を調べた結果(3gずつ5日間投与)
、投与直前にくらべ24%の低下がみられた。
(Ii) Using the same method as in Example 6,
Results of investigating terol-lowering effect (administered at 3g doses for 5 days)
, a 24% decrease compared to just before administration.

(111)実施例6と同じ方法により上記糠麹の血糖低
下作用を調べた結果(500m9/K9経口投与)、デ
ン粉のみ投与した対照群(6匹)にくらべ糠麹投与群(
6匹)では3紛後及び1時間後で血糖値それぞれ29%
及び21%の低下がみられた。
(111) As a result of investigating the hypoglycemic effect of the above bran koji using the same method as in Example 6 (oral administration of 500 m9/K9), the bran koji administration group (
6 animals), blood sugar levels were 29% each after 3 and 1 hour.
and a decrease of 21% was observed.

実施例 11(1)モナスカス●ルプロパンクタタス ATCCl6368を皺に少量の籾穀と60%の水を加
えて滅菌したものに接種し、常法により30℃で10日
間培養してr皺麹ョを得た。
Example 11 (1) Monascus Lepropanctatus ATCCl6368 was inoculated into a sterilized mixture of a small amount of rice grains and 60% water, and cultured at 30°C for 10 days by a conventional method to obtain a r. I got it.

山11)実施例6と同じ方法により上記皺麹のコレステ
ロール低下作用を調べた結果(3gずつ5日間投与)、
投与直前にくらべ24%の低下がみられた。
Mountain 11) As a result of investigating the cholesterol-lowering effect of the above wrinkled koji using the same method as in Example 6 (administering 3g for 5 days),
A 24% decrease was observed compared to just before administration.

(11i)実施例6と同じ方法により上記皺麹の血糖低
下作用を調べた結果血糖低下作用を調べた結果(500
m9/K9経口投与)、デン粉のみ投与した対照群(6
匹)にくらべ皺麹投与群(6匹)では3紛後及び1時間
後で血糖値それぞれ17%及び23%の低下がみられた
(11i) As a result of investigating the blood sugar lowering effect of the above-mentioned wrinkled koji using the same method as in Example 6 (500
m9/K9 oral administration), control group administered only starch (6
In the group treated with wrinkled koji (6 animals), a decrease in blood sugar levels of 17% and 23% was observed after 3 and 1 hour, respectively.

゛実施例 12 {1)モナスカス属八TCCl637Oを実施例6と同
じ方法により30℃で10日間培養して1米麹ョを得た
Example 12 {1) Monascus 8TCCl637O was cultured at 30°C for 10 days in the same manner as in Example 6 to obtain 1 rice malt.

(11)実施例6と同じ方法により上記米麹のコレステ
ロール低下作用を調べた結果(3gずつ5日間投与)、
投与直前にくらべ17%の低下がみられた。
(11) As a result of examining the cholesterol-lowering effect of the above rice malt using the same method as in Example 6 (administering 3 g for 5 days),
A 17% decrease was observed compared to immediately before administration.

実施例 13 2モナスカス属ATCCl6433を実施例6と同じ方
法により30℃で10日間培養して1米麹ョを得た。
Example 13 2 Monascus ATCCl6433 was cultured at 30° C. for 10 days in the same manner as in Example 6 to obtain 1 rice malt.

(11)実施例6と同じ方法により上記米麹の血糖低下
作用を調べた結果、対照群(6匹)にくらべ投与群(6
匹)ては3紛後及び1時間後てそれぞれ25%及び27
%の低下がみられた。
(11) As a result of investigating the blood sugar-lowering effect of the above rice malt using the same method as in Example 6, the control group (6 animals) was compared with the administration group (6 animals).
25% and 27% after 3 and 1 hour, respectively.
% decrease was observed.

実施例 14 (1)モナスカス属ATCCl6434を実施例10と
同じ方法により30℃て10日間培養して1米麹ョを得
た。
Example 14 (1) Monascus ATCCl6434 was cultured at 30°C for 10 days in the same manner as in Example 10 to obtain 1 rice malt.

(Ii)実施例6と同じ方法により上記糠麹のコレステ
ロール低下作用を調べた結果(3gずつ5日間投与)、
投与直前にくらべ18%の低下が得られた。
(Ii) As a result of examining the cholesterol-lowering effect of the above rice bran koji using the same method as in Example 6 (administration of 3 g for 5 days),
An 18% reduction was obtained compared to immediately before administration.

実施例 15 (1)モナスカス属ATCCl6666を実施例10と
同じ方法で培養し(30℃、10日間)、1糠麹ョを得
た。
Example 15 (1) Monascus ATCCl6666 was cultured in the same manner as in Example 10 (30°C, 10 days) to obtain 1 bran malt.

(11)実施例6と同じ方法により上記糠麹の血糖低下
作用を調べた結果(500mg/Kg経口投与)、対照
群にくらべ投与群では3扮後及び1時間後でそれぞれ1
6%及び18%の低下が得られた。
(11) As a result of examining the hypoglycemic effect of the above rice bran koji using the same method as in Example 6 (500 mg/Kg oral administration), the administration group received 1.
Reductions of 6% and 18% were obtained.

実施例 16{1)モナスカス属ATCCl6772を
実施例6と同じ方法により35゜Cで7日間培養して0
米麹ョを得た。
Example 16 {1) Monascus ATCCl6772 was cultured at 35°C for 7 days using the same method as in Example 6.
I got rice malt.

(Ii)実施例6と同じ方法により上記米麹のコレステ
ロール低下作用を調べた結果(3gずつ5日間投与)、
25%の低下が得られた。
(Ii) As a result of examining the cholesterol-lowering effect of the above rice malt using the same method as in Example 6 (administering 3 g for 5 days),
A reduction of 25% was obtained.

実施例 17 (1)モナスカス属ATCCl6773を実施例6と同
じ方法により30′Cで10日間培養して1米麹ョを得
た。
Example 17 (1) Monascus ATCCl6773 was cultured at 30'C for 10 days in the same manner as in Example 6 to obtain 1 rice malt.

(11)実施例6と同じ方法により上記米麹のコレステ
ロール低下作用を調べた結果(3gずつ5日間投与)、
21%の低下が得られた。
(11) As a result of examining the cholesterol-lowering effect of the above rice malt using the same method as in Example 6 (administering 3 g for 5 days),
A reduction of 21% was obtained.

実施例 18 (1)モナスカス属ΔTCCl6774を実施例11と
同じ方法により35℃で10日間培養してr皺麹ョを得
た。
Example 18 (1) Monascus ΔTCCl6774 was cultured at 35° C. for 10 days in the same manner as in Example 11 to obtain rrugated malt.

(Ii)実施例6と同じ方法により上記皺麹の血糖低下
作用を調べた結果(500m9/Kg経口投与)、対照
群(6匹)にくらべ投与群(6匹)では3紛後及び1時
間後で血糖値それぞれ33%及び17%の低下が得られ
た。
(Ii) As a result of examining the hypoglycemic effect of the above wrinkle koji using the same method as in Example 6 (oral administration of 500 m9/Kg), it was found that the administration group (6 animals) had a lower blood sugar level after 3 hours and 1 hour compared to the control group (6 animals). Later, a reduction in blood sugar levels of 33% and 17%, respectively, was obtained.

実施例 19 (1)モナスカス属ATCCl6775を実施例11と
同じ方法により35℃で10日間培養してr皺麹ョを得
た。
Example 19 (1) Monascus ATCCl6775 was cultured at 35° C. for 10 days in the same manner as in Example 11 to obtain rrugated malt.

(Ii)実施例6と同じ方法により上記皺麹のコレステ
ロール低下作用を調べた結果(3gずつ5日間投与)、
29%の低下が得られた。
(Ii) As a result of examining the cholesterol-lowering effect of the above wrinkled koji using the same method as in Example 6 (administering 3g for 5 days),
A reduction of 29% was obtained.

Claims (1)

【特許請求の範囲】[Claims] 1 モナスカス・パキシー、モナスカス・ピロウサス、
モナスカス・プビゲルス、モナスカス・ルーベル、モナ
スカス・ビトレウス、モナスカス・パープレウス、モナ
スカス・ルブロパンクタタスまたはこれらの変種または
変異株を培養して得られるコレステロール低下作用及び
血糖低下作用を有する麹。
1 Monascus paxii, Monascus pilousus,
A koji having a cholesterol-lowering effect and a blood sugar-lowering effect obtained by culturing Monascus pubigerus, Monascus rubel, Monascus vitraeus, Monascus purpureus, Monascus rubropanctatus, or their variants or mutants.
JP56033512A 1981-03-09 1981-03-09 malt Expired JPS6044914B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP56033512A JPS6044914B2 (en) 1981-03-09 1981-03-09 malt

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56033512A JPS6044914B2 (en) 1981-03-09 1981-03-09 malt

Publications (2)

Publication Number Publication Date
JPS57146570A JPS57146570A (en) 1982-09-10
JPS6044914B2 true JPS6044914B2 (en) 1985-10-05

Family

ID=12388593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56033512A Expired JPS6044914B2 (en) 1981-03-09 1981-03-09 malt

Country Status (1)

Country Link
JP (1) JPS6044914B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001204460A (en) * 2000-01-28 2001-07-31 Gunze Ltd Red yeast rice and its production method
JP2019030229A (en) * 2017-08-04 2019-02-28 マルコメ株式会社 Aspergillus oryzae, enzyme derived from aspergillus oryzae, blood glucose level rise inhibitor, food and beverage, pharmaceutical composition, food additive, supplement and manufacturing methods for the same, blood glucose level rise inhibiting method, and sugar uptake promotion method

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010095780A (en) * 2000-04-12 2001-11-07 나가오카 마사시 Embryo monascus
JP2006296251A (en) * 2005-04-19 2006-11-02 Gunze Ltd α-Glucosidase inhibitor
JP2021001143A (en) * 2019-06-21 2021-01-07 小林製薬株式会社 Chylous plasma improver

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001204460A (en) * 2000-01-28 2001-07-31 Gunze Ltd Red yeast rice and its production method
JP2019030229A (en) * 2017-08-04 2019-02-28 マルコメ株式会社 Aspergillus oryzae, enzyme derived from aspergillus oryzae, blood glucose level rise inhibitor, food and beverage, pharmaceutical composition, food additive, supplement and manufacturing methods for the same, blood glucose level rise inhibiting method, and sugar uptake promotion method

Also Published As

Publication number Publication date
JPS57146570A (en) 1982-09-10

Similar Documents

Publication Publication Date Title
TWI636739B (en) Bacillus amyloliquefaciens, grain yeast, preparation method thereof, and use thereof, food composition, composition for thrombolysis, composition for improving digestion, composition for preventing,improving or treating enteritis, intestinal weakening or
JP2002191354A (en) Production method of mushroom mycelium and use thereof
JP4621444B2 (en) Method for producing antitumor substance
KR101971546B1 (en) Food composition for improving learning and memory function comprising lactic acid bacteria, hericium erinaceus extract and ginkgo leaf extract
JP3244468B2 (en) Production method of turmeric ingredients
JP2001521728A (en) Production of hydrolysates
JP4522522B2 (en) Sockeye and its manufacturing method
CN1144873C (en) Novel clostridium butyricum and application thereof
JPS6044914B2 (en) malt
CN112544872A (en) Preparation and application of fat substitute
KR100435267B1 (en) Method for the production of monascus inoculation germinated rice brown and it productive method for food
KR102345416B1 (en) Doenjang with rice-nuruk and manufacturing method thereof
WO2002052952A1 (en) Process for the preparation of red barley by solid-phase fermentation of monascaceae strain containing selenium
JP2664311B2 (en) New food and drink ingredients
JPS5843783A (en) Koji (rice malt)
JP4363692B2 (en) Method for producing red yeast rice rich in blood pressure lowering component
JP2002275087A (en) Antidiabetic medicine and food for preventing diabetes
JP2670742B2 (en) α-amylase inhibitor
JP2006296251A (en) α-Glucosidase inhibitor
KR20210052639A (en) Manufacturing method of composition comprising mushroom mycelia for glucose level
KR102482895B1 (en) Manufacturing method of uncooked food using filtrate of loess suspension and fermentation fruit broth
JP7291369B2 (en) Visceral fat reducing agent and food composition for reducing visceral fat
JPH0376573A (en) Production of wheat ang-khak
JP2000106834A (en) Embryo anka
JP2000270841A (en) Production of amino acid-rich ang-khak